IGF1R and adrenal cortex carcinoma: Early clinical attempt of IGF1R inhibitors, including linsitinib (OSI-906) and cixutumumab (IMC-A12), have demonstrated some preliminary activity against ACC, including partial responses in certain cases (18, 45).